ArticleMedicine2025
Global, regional, and national burden of kidney cancer, 1990 to 2021, and projections to 2050: A Global Burden of Disease Study 2021.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the Global Burden of Disease Study (GBD) 2019 offered important insights into kidney cancer, no research has yet examined the updated GBD 2021. Therefore, utilizing the GBD 2021, this study provides updated estimates of kidney cancer burden, identifies attributable risk factors, and projects future trends through 2050. Data on the global and regional burden of kidney cancer from 1990 to 2021 were extracted from the GBD 2021, stratified by age, sex, Sociodemographic Index (SDI), and geographical region. Mortality-to-incidence ratio and annual percentage changes on mortality, disability-adjusted life year (DALY), and incidence were analyzed to assess trends of the burden. Attributable risk factors (i.e., tobacco use, high body mass index, and occupational risks) were examined. Additionally, future mortality and DALYs up to 2050 were forecasted by integrating independent drivers, with analyses conducted under a baseline scenario and an improved scenario with enhanced behavioral and metabolic risk factors. In 2021, kidney cancer caused 161.19 thousand (95% uncertainty interval, 150.32-169.35) deaths, 4.02 million (3.81-4.25) DALYs, 387.83 thousand (365.36-406.64) incident cases, and 0.42 (0.39-0.46) mortality-to-incidence ratio globally. While the absolute burden of kidney cancer increased from 1990 to 2021, age-standardized rates decreased. The burden was higher in males, older populations, and regions with higher SDI, although recent declines in these regions contrast with rising burden in lower SDI regions. High body mass index was the leading risk factor, particularly in females, while tobacco was more prominent in males. By 2050, the global age-standardized DALY rate is projected to rise slightly to 47.72 (35.89-63.05) per 100,000. However, under a scenario with improved behavioral and metabolic risks, it is expected to decline to 35.86 (26.71-48.11), except in South Asia and Sub-Saharan Africa. Addressing sociodemographic disparities in kidney cancer burden and strengthening global efforts are essential. Managing behavioral and metabolic risks could reduce the kidney cancer burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.